BCRX BioCryst Pharmaceuticals, Inc. - Common Stock

NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗
$9.94
价格 · 八月 19, 2026
截至...的财报数据 八月 5, 2026
52周区间
$6–$11
75% of range
分析师评级
BUY
17 analysts
目标价
$21
+109% upside
P/E (TTM)
9.8
ROE
-97.6%
净利润率
30.2%

关于 BioCryst Pharmaceuticals, Inc. - Common Stock 公司概况（来自维基百科）

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.

阅读更多

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.

History

The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.

In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.

Pipeline

BioCryst’s core development programs include:

Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).

FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.

Berotralstat has a PDUFA date for FDA approval on December 3, 2020.

On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.

BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.

FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).

Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.

Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.

In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.

BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.

In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.

In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.

In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.

来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗

Wikidata ↗

BCRX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围

价格
$9.94
市值
$2.52B
P/E (TTM)
9.8
每股收益 (TTM)
$1.21
营收 (TTM)
$875M
股息收益率
—
ROE
-97.6%
负债/权益
0.0
52周区间
$6 – $11

BCRX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图

10年表现 收入、净利润、利润率和每股收益趋势

营收与净利润 $875M
10-point trend, +3219.7%
2016-12-31 → 2025-12-31
EPS $1.21
6-point trend, +211.0%
2020-12-31 → 2025-12-31
自由现金流 $345M
9-point trend, +687.4%
2016-12-31 → 2025-12-31
利润率 30.2%

估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？

指标
5年趋势
BCRX
同行中位数
P/E (TTM)
5-point trend, +147.9%
9.8
97.6
P/S (TTM) (市销率 (TTM))
5-point trend, -88.3%
2.9
7.7
P/B (市净率)
5-point trend, +41.6%
-21.2
8.0
EV / EBITDA (企业价值 / EBITDA)
5-point trend, +132.8%
6.6
—
Price / FCF (股价/自由现金流)
5-point trend, +127.3%
7.3
—

盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)

指标
5年趋势
BCRX
同行中位数
Operating Margin (营业利润率)
5-point trend, +134.5%
39.0%
—
Net Profit Margin (净利润率)
5-point trend, +125.8%
30.2%
-51.7%
ROA
5-point trend, +231.7%
52.5%
-44.2%
ROE
5-point trend, -167.3%
-97.6%
-63.5%
ROIC
5-point trend, +54.3%
-282.4%
—

财务健康 债务、流动性、偿付能力 — 资产负债表强度

指标
5年趋势
BCRX
同行中位数
Debt / Equity (负债/股东权益比率)
5-point trend, +100.0%
0.0
18.7
Current Ratio (流动比率)
5-point trend, -62.2%
2.1
4.9
Quick Ratio (速动比率)
5-point trend, -62.2%
1.9
—

成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)

指标
5年趋势
BCRX
同行中位数
Revenue YoY (营收同比增长)
5-point trend, +456.6%
94.1%
—
Revenue CAGR 3Y (营收3年复合年增长率)
5-point trend, +456.6%
47.8%
—
Revenue CAGR 5Y (营收5年复合年增长率)
5-point trend, +456.6%
117.9%
—

每股指标 每股收益 (EPS)、每股净资产、每股现金流、每股股息

指标
5年趋势
BCRX
同行中位数
EPS (Diluted) (EPS (稀释))
5-point trend, +217.5%
$1.21
—

资本效率 资产周转率、库存周转率、应收账款周转率

指标
5年趋势
BCRX
同行中位数

BCRX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间

买入 17 位分析师
  • 强烈买入 5 29.4%
  • 买入 10 58.8%
  • 持有 2 11.8%
  • 卖出 0 0.0%
  • 强烈卖出 0 0.0%

12个月价格目标

11 位分析师 · 2026-08-17
中位数目标 $17.00 +71.0%
平均目标 $20.82 +109.4%

收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期

平均惊喜
0.02%
期间 EPS Actual EPS 预期 惊喜
2026年6月30日 $0.30 $0.12 0.18%
2026年3月31日 $-0.09 $0.05 -0.14%
2025年12月31日 $0.01 $0.04 -0.03%
2025年9月30日 $0.06 $0.04 0.02%
2025年6月30日 $0.04 $0.01 0.03%
2025年3月31日 $0.00 $-0.07 0.07%

同行比较（GICS 子行业） 关键指标与行业同行对比

股票代码 市值 P/E 营收同比增长 净利润率 ROE 毛利率
BCRX $1.66B 6.4 94.1% 30.2% -97.6% —
BEAM $2.82B -34.2 120.0% -57.2% -7.0% —
KOD $1.73B -6.5 — — -202.0% —
SLS $577M -15.1 — — -55.4% —
RARE $2.22B -3.9 20.2% -85.4% -1613.2% —
COAG — — — — — —
KLRA — — — — — —
CDNA $959M -47.1 13.8% -5.6% -6.8% —
PGEN $1.48B -3.1 146.7% -2588.2% 3159.1% —
VERA — -10.9 — — -55.9% —
MLYS $2.96B -15.8 — — -32.2% —

完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表

损益表 16
BCRX 的年度损益表数据
指标 趋势 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +6328.8% $875M $451M $331M $271M $157M $18M $49M $21M $25M $26M $48M $14M
Cost of Revenue 11-point trend, +1907400.0% $19M $12M $4M $6M $7M $2M $4M · $1M $2M $1M $1.0K
R&D Expense 12-point trend, +220.7% $166M $175M $217M $253M $209M $123M $107M $85M $67M $61M $73M $52M
SG&A Expense 12-point trend, +4572.9% $349M $266M $214M $159M $119M $68M $37M $30M $14M $11M $13M $7M
Operating Expenses 12-point trend, +799.1% $534M $453M $435M $419M $335M $193M $148M $115M $83M $75M $88M $59M
Operating Income 12-point trend, +845.0% $341M $-3M $-104M $-148M $-178M $-175M $-99M $-94M $-57M $-49M $-39M $-46M
Interest Expense 10-point trend, +2065.6% · · $108M $99M $59M $15M $12M $9M $9M $6M $5M $5M
Other Non-op 4-point trend, +23.3% $-74M $-84M $-123M $-96M · · · · · · · ·
Pretax Income 7-point trend, +345.5% $267M $-87M $-226M $-244M $-182M $-183M $-109M · · · · ·
Income Tax 11-point trend, +3530000.00 $4M $2M $310.0K $3M $2M $0 $0 $0 $0 $0 $0 ·
Net Income 12-point trend, +683.9% $264M $-89M $-227M $-247M $-184M $-183M $-109M $-101M $-66M $-55M $-43M $-45M
EPS (Basic) 6-point trend, +215.6% $1.26 $-0.43 $-1.18 $-1.33 $-1.03 $-1.09 · · · · · ·
EPS (Diluted) 6-point trend, +211.0% $1.21 $-0.43 $-1.18 $-1.33 $-1.03 $-1.09 · · · · · ·
Shares (Basic) 6-point trend, +25.5% 209,893,000 206,696,000 192,198,000 185,908,000 179,117,000 167,267,000 · · · · · ·
Shares (Diluted) 12-point trend, +227.3% 218,581,000 206,696,000 192,198,000 185,908,000 179,117,000 167,267,000 115,600,000 103,185,000 84,451,000 73,699,000 72,901,000 66,773,000
EBITDA 11-point trend, +850.9% $342M $-1M $-102M $-147M $-177M $-174M $-99M $-93M · $-48M $-39M $-46M
资产负债表 27
BCRX 的年度资产负债表数据
指标 趋势 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +64.5% $90M $105M $111M $305M $504M $272M $114M $27M $50M $22M $29M $55M
Short-term Investments 2-point trend, -14.4% $185M $216M · · · · · · · · · ·
Receivables 12-point trend, +2675.2% $107M $79M $57M $51M $29M $9M $22M $4M $6M $9M $6M $4M
Inventory 11-point trend, +690.3% $5M $8M $29M $28M $16M $7M $0 $2M · $500.0K $2M $683.0K
Prepaid Expense 12-point trend, +178.4% $17M $14M $20M $13M $10M $6M $4M $2M $1M $1M $3M $6M
Current Assets 12-point trend, +352.6% $404M $422M $496M $516M $566M $324M $164M $114M $125M $67M $64M $89M
PP&E (Net) 12-point trend, +4143.0% $9M $8M $8M $9M $9M $7M $7M $9M $10M $10M $5M $207.0K
PP&E (Gross) 12-point trend, +27.7% $18M $20M $19M $18M $17M $14M $14M $15M $15M $15M $19M $14M
Accum. Depreciation 12-point trend, -33.0% $9M $12M $11M $10M $8M $7M $7M $6M $5M $5M $14M $14M
Other Non-current Assets 12-point trend, -6.0% $6M $5M $80.0K $7M $6M $4M $4M $978.0K $2M $4M $5M $6M
Total Assets 12-point trend, +275.6% $514M $490M $517M $550M $588M $335M $175M $147M $178M $90M $122M $137M
Accounts Payable 12-point trend, +455.5% $16M $12M $21M $14M $28M $19M $14M $8M $6M $4M $9M $3M
Accrued Liabilities 12-point trend, +1015.8% $126M $113M $103M $88M $73M $34M $21M $16M $13M $11M $16M $11M
Short-term Debt 7-point trend, +0.0% · · · · · $30M $30M $29M $29M $28M $28M $30M
Current Liabilities 12-point trend, +242.2% $196M $160M $150M $106M $104M $106M $92M $69M $75M $54M $62M $57M
Capital Leases 6-point trend, +121.4% $9M $8M $8M $4M $6M $4M · · · · · ·
Other Non-current Liabilities · · · · · · · $3M · · · ·
Total Liabilities 3-point trend, -34.9% $633M $966M $972M · · · · · · · · ·
Long-term Debt 6-point trend, +1196.3% · · · · $298M $123M $50M $30M $23M $23M · ·
Total Debt 11-point trend, -100.0% $0 $315M $303M $232M $136M $150M $30M $29M · $28M $30M $30M
Common Stock 12-point trend, +196.0% $2M $2M $2M $2M $2M $2M $2M $1M $984.0K $738.0K $734.0K $720.0K
Paid-in Capital 12-point trend, +155.1% $1.38B $1.29B $1.22B $1.16B $1.10B $1.00B $877M $780M $715M $567M $558M $543M
Retained Earnings 12-point trend, -221.9% $-1.51B $-1.77B $-1.68B $-1.45B $-1.21B $-1.02B $-841M $-732M $-632M $-566M $-511M $-468M
AOCI 12-point trend, +129.2% $38.0K $921.0K $1M $26.0K $177.0K $3.0K $39.0K $-297.0K $-243.0K $-12.0K $-206.0K $-130.0K
Stockholders' Equity 12-point trend, -257.5% $-119M $-476M $-456M $-295M $-107M $-19M $38M $49M $84M $2M $48M $76M
Liabilities + Equity 12-point trend, +275.6% $514M $490M $517M $550M $588M $335M $175M $147M $178M $90M $122M $137M
Shares Outstanding 12-point trend, +196.1% 213,060,000 208,543,000 205,771,000 187,906,000 184,350,000 176,883,000 154,082,000 110,063,000 98,411,000 73,782,000 73,355,000 71,955,000
现金流 16
BCRX 的年度现金流数据
指标 趋势 202520242023202220212020201920182017201620152014
D&A 12-point trend, +684.7% $1M $1M $2M $1M $777.0K $748.0K $724.0K $770.0K $704.0K $483.0K $180.0K $177.0K
Stock-based Comp 12-point trend, +735.9% $85M $65M $56M $45M $35M $15M $18M $9M $13M $8M $10M $10M
Deferred Tax 5-point trend, -662.3% $-1M $-354.0K $-682.0K $11.0K $-159.0K · · · · · · ·
Other Non-cash 11-point trend, +53.3% $-2M $-29M $75M $39M $6M $30M $870.0K $-1M · $-7M $20M $-4M
Operating Cash Flow 12-point trend, +1001.1% $347M $-52M $-95M $-162M $-142M $-135M $-90M $-93M $-41M $-53M $-13M $-39M
CapEx 12-point trend, +2228.3% $2M $1M $2M $1M $2M $514.0K $343.0K $366.0K $328.0K $5M $5M $106.0K
Investing Cash Flow 11-point trend, +23.9% $-14M $53M $-131M $-128M $16M $-7M $78M $5M $-65M $23M $-18M ·
Debt Issued 5-point trend, +0.00 $0 $0 $300M $73M $0 · · · · · · ·
Net Debt Issued 3-point trend, -200.0% $-300M $0 $300M · · · · · · · · ·
Stock Issued 8-point trend, -100.0% · · $0 $0 $50M $93M $58M $53M $134M · · $107M
Net Stock Activity 7-point trend, -100.0% · · $0 $0 $50M $93M $58M $53M · · · $107M
Financing Cash Flow 11-point trend, -6486.8% $-350M $-6M $32M $88M $360M $301M $99M $63M $136M $23M $5M ·
Net Change in Cash 12-point trend, -144.9% $-15M $-6M $-194M $-201M $233M $159M $87M $-25M $30M $-7M $-26M $33M
Taxes Paid 3-point trend, +95.5% $3M $2M $1M · · · · · · · · ·
Free Cash Flow 11-point trend, +992.2% $345M $-53M $-97M $-163M $-145M $-138M $-90M $-93M · $-59M $-18M $-39M
Levered FCF 4-point trend, -35.1% · · $-206M $-263M $-205M $-152M · · · · · ·
盈利能力 7
BCRX 的年度盈利能力数据
指标 趋势 202520242023202220212020201920182017201620152014
Operating Margin 11-point trend, +111.6% 39.0% -0.56% -31.3% -54.8% -113.1% -981.1% -203.7% -456.2% · -184.4% -81.7% -336.4%
Net Margin 11-point trend, +109.1% 30.2% -19.7% -68.4% -91.2% -117.1% -1026.4% -223.0% -490.2% · -209.2% -89.1% -332.1%
Pretax Margin 6-point trend, +103.0% 30.6% -19.3% -68.3% -90.2% -115.7% -1026.4% · · · · · ·
EBITDA Margin 11-point trend, +111.7% 39.1% -0.29% -30.8% -54.3% -112.6% -976.9% -202.2% -452.5% · -182.6% -81.4% -335.0%
ROA 11-point trend, +208.0% 52.5% -17.6% -42.5% -43.4% -39.9% -71.7% -67.6% -62.3% · -52.0% -32.9% -48.7%
ROE 11-point trend, +19.5% -97.6% 18.8% 52.3% 92.0% 144.9% -2543.5% 7257.4% -165.8% · -223.7% -69.8% -121.3%
ROIC 6-point trend, -110.8% -282.4% 1.6% 68.2% 238.4% -618.4% -133.9% · · · · · ·
流动性与偿付能力 5
BCRX 的年度流动性与偿付能力数据
指标 趋势 202520242023202220212020201920182017201620152014
Current Ratio 11-point trend, +33.2% 2.1 2.6 3.3 4.9 5.5 3.1 1.8 1.6 · 1.2 1.0 1.5
Quick Ratio 11-point trend, +105.8% 1.9 1.1 1.1 3.4 5.1 2.7 1.5 0.4 · 0.6 0.5 0.9
Debt / Equity 11-point trend, -100.0% 0.0 -0.7 -0.7 -0.8 -1.3 -7.8 0.8 0.6 · 17.9 0.6 0.4
LT Debt / Equity 6-point trend, +100.0% 0.0 -0.7 -0.7 -0.8 -1.3 -6.2 · · · · · ·
Interest Coverage 9-point trend, +89.5% · · -1.0 -1.5 -3.0 -12.1 -8.4 -10.3 · -7.5 -7.6 -9.2
效率 3
BCRX 的年度效率数据
指标 趋势 202520242023202220212020201920182017201620152014
Asset Turnover 11-point trend, +1088.9% 1.7 0.9 0.6 0.5 0.3 0.1 0.3 0.1 · 0.2 0.4 0.1
Inventory Turnover 9-point trend, +97455.2% 2.8 0.4 0.2 0.3 0.6 0.4 · · · 2.2 1.2 0.0
Receivables Turnover 10-point trend, -1.6% 9.4 6.6 6.2 6.8 8.3 1.2 3.7 4.0 · 3.5 9.6 ·
每股 5
BCRX 的年度每股数据
指标 趋势 202520242023202220212020201920182017201620152014
Book Value / Share 11-point trend, -153.2% $-0.56 $-2.28 $-2.21 $-1.57 $-0.58 $-0.11 $0.25 $0.45 · $0.02 $0.65 $1.05
Revenue / Share 10-point trend, +504.6% $4.00 $2.18 $1.72 $1.46 $0.88 $0.11 $0.42 $0.20 · $0.36 $0.66 ·
Cash Flow / Share 10-point trend, +983.4% $1.59 $-0.25 $-0.49 $-0.87 $-0.79 $-0.82 $-0.77 $-0.90 · $-0.73 $-0.18 ·
Cash / Share 11-point trend, -44.4% $0.42 $0.50 $0.54 $1.62 $2.74 $1.54 $0.74 $0.24 · $0.30 $0.39 $0.76
EPS (TTM) 11-point trend, +301.7% $1.21 $-0.43 $-1.18 $-1.33 $-1.03 $-1.09 $-0.61 $-0.61 $-0.61 $-0.61 $-0.60 ·
增长率 3
BCRX 的年度增长率数据
指标 趋势 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -88.0% 94.1% 36.0% 22.4% 72.3% 782.4% · · · · · · ·
Revenue CAGR 3Y 3-point trend, -71.0% 47.8% 42.1% 165.0% · · · · · · · · ·
Revenue CAGR 5Y 117.9% · · · · · · · · · · ·
估值 (TTM) 13
BCRX 的年度估值 (TTM)数据
指标 趋势 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +6328.8% $875M $451M $331M $271M $157M $18M $49M $21M $25M $26M $48M $14M
Net Income TTM 12-point trend, +683.9% $264M $-89M $-227M $-247M $-184M $-183M $-109M $-101M $-66M $-55M $-43M $-45M
Market Cap 11-point trend, +89.9% $1.66B $1.57B $1.23B $2.16B $2.55B $1.32B $532M $888M · $467M $757M $875M
Enterprise Value 11-point trend, +63.1% $1.39B $1.78B $1.43B $2.08B $2.18B $1.20B $447M $891M · $473M $758M $850M
P/E 11-point trend, +137.5% 6.4 -17.5 -5.1 -8.6 -13.4 -6.8 -5.7 -13.2 -8.0 -10.4 -17.2 ·
P/S 11-point trend, -97.0% 1.9 3.5 3.7 8.0 16.2 74.0 10.9 43.0 · 17.7 15.7 64.3
P/B 11-point trend, -220.6% -13.9 -3.3 -2.7 -7.3 -23.9 -68.4 13.9 18.0 · 296.0 15.9 11.6
P / Cash Flow 11-point trend, +121.1% 4.8 -30.1 -13.0 -13.3 -18.0 -9.6 -5.9 -9.6 · -8.7 -57.7 -22.7
P / FCF 11-point trend, +121.3% 4.8 -29.5 -12.7 -13.2 -17.7 -9.6 -5.9 -9.6 · -8.0 -41.5 -22.6
EV / EBITDA 11-point trend, +121.7% 4.1 -1371.2 -14.0 -14.2 -12.3 -6.9 -4.5 -9.5 · -9.8 -19.3 -18.7
EV / FCF 11-point trend, +118.3% 4.0 -33.5 -14.6 -12.8 -15.1 -8.7 -5.0 -9.6 · -8.1 -41.6 -22.0
EV / Revenue 11-point trend, -97.5% 1.6 3.9 4.3 7.7 13.9 67.1 9.2 43.1 · 18.0 15.7 62.5
Earnings Yield 11-point trend, +367.0% 15.5% -5.7% -19.7% -11.6% -7.4% -14.6% -17.7% -7.6% -12.4% -9.6% -5.8% ·

财务报表 损益表、资产负债表、现金流量表 — 年度，近5年

损益表
2025-12-312024-12-312023-12-312022-12-312021-12-31
收入 $875M$451M$331M$271M$157M
营业利润率 % 39.0%-0.56%-31.3%-54.8%-113.1%
净收入 $264M$-89M$-227M$-247M$-184M
稀释后每股收益 (EPS) $1.21$-0.43$-1.18$-1.33$-1.03
资产负债表
2025-12-312024-12-312023-12-312022-12-312021-12-31
负债/股东权益比率 0.0-0.7-0.7-0.8-1.3
流动比率 2.12.63.34.95.5
速动比率 1.91.11.13.45.1
现金流
2025-12-312024-12-312023-12-312022-12-312021-12-31
自由现金流 $345M$-53M$-97M$-163M$-145M

最新新闻 提及该公司的近期头条新闻

我的指标 您的个人关注列表 — 来自完整基本面的选定行

📊

选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。

您的选择已保存，并会跟随您浏览所有股票。

机构持有人 (13F) 346 家申报者 · $2.1B 总计 · 截至 2026年6月30日

在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。

机构活动 — Q2 2026 与上一季度对比
新仓位 已退出持仓 增加 减少 净股数变动
63 (-7 与上一季度对比) 34 (-7 与上一季度对比) 130 (+19 与上一季度对比) 83 (+3 与上一季度对比) +25.9M

与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。

机构 价值 股份 % 已追踪的13F 类型
RA CAPITAL MANAGEMENT, L.P. $158271860 15827186 7.51% 股份
STATE STREET CORP $151910980 15191098 7.21% 股份
DEERFIELD MANAGEMENT COMPANY, L.P. $150964030 15096403 7.16% 股份
VANGUARD CAPITAL MANAGEMENT LLC $113642360 11364236 5.39% 股份
VANGUARD PORTFOLIO MANAGEMENT LLC $111391580 11139158 5.29% 股份
TCG Crossover Management, LLC $110209680 11020968 5.23% 股份
PERCEPTIVE ADVISORS LLC $103088880 10308888 4.89% 股份
JANUS HENDERSON GROUP PLC $83961589 8814865 3.98% 股份
Vestal Point Capital, LP $83000000 8300000 3.94% 股份
TWO SIGMA INVESTMENTS, LP $67753490 6775349 3.21% 股份
GEODE CAPITAL MANAGEMENT, LLC $53581572 5356880 2.54% 股份
Aberdeen Group plc $53108710 5310871 2.52% 股份
Frazier Life Sciences Management, L.P. $40092400 4009240 1.90% 股份
GOLDMAN SACHS GROUP INC $35393210 3539321 1.68% 股份
MILLENNIUM MANAGEMENT LLC $33947290 3394729 1.61% 股份
TWO SIGMA ADVISERS, LP $31895074 4089112 1.51% 股份
RP Management, LLC $28846155 3846154 1.37% 股份
DIMENSIONAL FUND ADVISORS LP $27161110 2716111 1.29% 股份
Fisher Asset Management, LLC $26040270 2604027 1.24% 股份
RENAISSANCE TECHNOLOGIES LLC $25302900 2530290 1.20% 股份
Kynam Capital Management, LP $25226600 2522660 1.20% 股份
Candriam S.C.A. $25125293 2514949 1.19% 股份
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $23532910 2353291 1.12% 股份
RICE HALL JAMES & ASSOCIATES, LLC $23320430 2332043 1.11% 股份
AQR CAPITAL MANAGEMENT LLC $21850110 2185011 1.04% 股份
Nantahala Capital Management, LLC $19011600 1901160 0.90% 股份
Eversept Partners, LP $18656530 1865653 0.89% 股份
ORBIMED ADVISORS LLC $18520000 1852000 0.88% 股份
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND $18449120 1844912 0.88% 股份
VANGUARD FIDUCIARY TRUST CO $17595730 1759573 0.83% 股份
CITADEL ADVISORS LLC $17591600 1759160 0.83% 股份
IMC-Chicago, LLC $16343360 1634336 0.78% 股份
Parkman Healthcare Partners LLC $16242790 1624279 0.77% 股份
JANE STREET GROUP, LLC $14267680 1426768 0.68% 股份
OP Asset Management Ltd $13409900 1340990 0.64% 股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP $11956510 1195651 0.57% 股份
Pictet Asset Management Holding SA $11951392 1249771 0.57% 股份
BNP PARIBAS FINANCIAL MARKETS $11740520 1174052 0.56% 股份
FIRST TRUST ADVISORS LP $11204690 1120469 0.53% 股份
JANE STREET GROUP, LLC $9944130 994413 0.47% 买入期权
Cubist Systematic Strategies, LLC $9462419 1246696 0.45% 股份
MOORE CAPITAL MANAGEMENT, LP $8483360 848336 0.40% 股份
FMR LLC $8062330 806233 0.38% 股份
BANK OF AMERICA CORP /DE/ $7754020 775402 0.37% 股份
ExodusPoint Capital Management, LP $7449170 744917 0.35% 股份
Man Group plc $7324800 732480 0.35% 股份
Rosalind Advisors, Inc. $7215040 721504 0.34% 股份
Schonfeld Strategic Advisors LLC $7108160 710816 0.34% 股份
BlackRock, Inc. $5984400 598440 0.28% 股份
Elmind Capital, LP $5200000 520000 0.25% 股份
Bridgewater Associates, LP $4910570 491057 0.23% 股份
NAN FUNG TRINITY (HK) LTD $4500000 450000 0.21% 股份
SPHERA FUNDS MANAGEMENT LTD. $4220510 422051 0.20% 股份
Swiss National Bank $4152680 415268 0.20% 股份
Susquehanna Portfolio Strategies, LLC $4047040 404704 0.19% 股份
DAFNA Capital Management LLC $4002480 400248 0.19% 股份
Hudson Bay Capital Management LP $4000000 400000 0.19% 股份
Aquatic Capital Management LLC $3628950 362895 0.17% 股份
DOLIVER CAPITAL ADVISORS, INC. $3563603 374328 0.17% 股份
Assenagon Asset Management S.A. $3530440 353044 0.17% 股份
Kodai Capital Management LP $3515993 468799 0.17% 股份
MACKENZIE FINANCIAL CORP $3472990 347299 0.16% 股份
CITIGROUP INC $3467520 346752 0.16% 股份
Phocas Financial Corp. $3405410 340541 0.16% 股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP $3238000 323800 0.15% 买入期权
ALPS ADVISORS INC $3179600 317960 0.15% 股份
ALLIANCEBERNSTEIN L.P. $3121694 327909 0.15% 股份
RHUMBLINE ADVISERS $2798390 279839 0.13% 股份
Rafferty Asset Management, LLC $2656180 265618 0.13% 股份
Point72 Asset Management, L.P. $2609170 260917 0.12% 股份
Nuveen, LLC $2599030 259903 0.12% 股份
NFJ INVESTMENT GROUP, LLC $2568330 256833 0.12% 股份
Nebula Research & Development LLC $2567121 286509 0.12% 股份
WINTON GROUP Ltd $2556000 255600 0.12% 股份
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $2459444 258345 0.12% 股份
MARTINGALE ASSET MANAGEMENT L P $2425080 242508 0.12% 股份
WELLINGTON MANAGEMENT GROUP LLP $2324670 232467 0.11% 股份
CITADEL ADVISORS LLC $2322000 232200 0.11% 买入期权
IEQ CAPITAL, LLC $2274210 227421 0.11% 股份
Bank of New York Mellon Corp $2251670 225167 0.11% 股份
D. E. Shaw & Co., Inc. $2249120 224912 0.11% 股份
JUPITER ASSET MANAGEMENT LTD $2221030 222103 0.11% 股份
HUSSMAN STRATEGIC ADVISORS, INC. $2100000 210000 0.10% 股份
PFM Health Sciences, LP $2073570 207357 0.10% 股份
VANGUARD ASSET MANAGEMENT, Ltd $1962800 196280 0.09% 股份
TUDOR INVESTMENT CORP ET AL $1951280 195128 0.09% 股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1853000 185300 0.09% 卖出期权
VIRGINIA RETIREMENT SYSTEMS ET Al $1820161 233354 0.09% 股份
Engineers Gate Manager LP $1750020 175002 0.08% 股份
Squarepoint Ops LLC $1747140 174714 0.08% 股份
QTR Family Wealth, LLC $1610820 161082 0.08% 股份
Gotham Asset Management, LLC $1564210 156421 0.07% 股份
CITADEL ADVISORS LLC $1450000 145000 0.07% 卖出期权
Corient Private Wealth LP $1429860 142986 0.07% 股份
NEW YORK STATE COMMON RETIREMENT FUND $1386570 138657 0.07% 股份
Quantinno Capital Management LP $1374530 137453 0.07% 股份
MetLife Investment Management, LLC $1356700 135670 0.06% 股份
PROFUND ADVISORS LLC $1340340 134034 0.06% 股份
Virtus Investment Advisers, LLC $1336640 133664 0.06% 股份
ADAR1 Capital Management, LLC $1330000 133000 0.06% 股份

公司内部人士 51 位内幕人士 · 21 位高管 · 30 位董事

内部人士 角色 上次活动 持股数量 买入 12个月 卖出 12个月 净额 12个月
Babar Ghias Chief Financial Officer 2025年12月17日 A 268700 0 0 $0
Anthony Doyle Chief Financial Officer 2024年12月19日 A 377867 0 0 $0
Thomas R Staab II Senior Vice President and CFO 2020年2月21日 A 125176 0 0 $0
Stuart Grant SR VP & CFO 2011年3月16日 M 57102 0 0 $0
Charles K Gayer President and CCO 2025年12月22日 M 952583 0 0 $0
Claude J Bennett Chief Operating Officer 2008年3月14日 A 65730 0 0 $0
Alane P Barnes Chief Legal Officer 2026年5月13日 M 400703 0 7 $-3461969
Sandeep Menon Chief R&D Officer 2026年4月6日 A 205150 0 0 $0
Helen M. Thackray Chief R&D Officer 2025年3月31日 F 377318 0 0 $0
Michael L Jones Exec. Director, Finance - PAO 2022年12月19日 A 16653 0 0 $0
Yarlagadda S Babu Chief Discovery Officer 2022年11月14日 M 298541 0 0 $0
William P Sheridan Chief Medical Officer 2022年3月10日 M 37954 0 0 $0
Megan Sniecinski Chief Business Officer 2020年12月15日 A 45000 0 0 $0
Lynne Powell Senior VP - CCO 2019年1月28日 M 0 0 0 $0
David Mccullough VP 2012年3月15日 F 24124 0 0 $0
Robert S Lowrey Controller, PAO 2011年2月7日 A 9766 0 0 $0
Mike Mills Principal Accounting Officer 2010年3月12日 M 0 0 0 $0
Michael A Darwin Principal Accounting Officer 2008年7月31日 P 3048 0 0 $0
Jonathan M Nugent VP Corp Communications 2007年7月31日 P 508 0 0 $0
James W Alexander SR. VP, Chief Medical Officer 2007年7月31日 P 3659 0 0 $0
Randall B Riggs Senior VP Business Development 2007年5月16日 A 1928 0 0 $0
Amy E Mckee 董事 2026年6月11日 A 47177 0 1 $-100285
Theresa Heggie 董事 2026年6月11日 A 80646 0 1 $-504823
Machelle Sanders 董事 2026年6月11日 A 45936 0 1 $-68544
Jill C. Milne 董事 2026年6月11日 A 31938 0 0 $0
Steven Frank 董事 2026年6月11日 A 35459 0 0 $0
Steven K Galson 董事 2026年6月11日 A 27794 0 0 $0
Jon P Stonehouse 董事 2026年6月11日 A 1339775 0 0 $0
Vincent Milano 董事 2026年6月11日 A 108483 0 0 $0
Alan G Levin 董事 2026年6月11日 A 79565 0 0 $0
Nancy J Hutson 董事 2025年6月12日 A 99138 0 0 $0
George B Abercrombie 董事 2024年6月12日 A 36431 0 0 $0
Steve Aselage 董事 2024年6月12日 A 70159 0 0 $0
Kenneth B Lee JR 董事 2023年6月13日 A 68863 0 0 $0
Robert Alexander Ingram 董事 2023年2月28日 A 100198 0 0 $0
Stanley C Erck 董事 2018年11月28日 M 48333 0 0 $0
Fred Cohen 董事 2018年6月20日 A 119410 0 0 $0
Sanj K Patel 董事 2017年5月24日 A — 0 0 $0
Charles A Sanders 董事 2016年2月29日 A 12971 0 0 $0
Peder Jensen 董事 2014年5月2日 A 60000 0 0 $0
John L Higgins 董事 2012年5月23日 A — 0 0 $0
HOROVITZ ZOLA P 董事 2012年5月23日 A 3000 0 0 $0
Stephen R Biggar 董事 2011年5月12日 A — 0 0 $0
Beth C Seidenberg 董事 2010年5月13日 A 3000 0 0 $0
William W Featheringill 董事 2010年5月13日 A 231538 0 0 $0
William M Spencer III 董事 2007年5月16日 A 186761 0 0 $0
Joseph H Sherrill JR 董事 2007年5月16日 A 451900 0 0 $0
Charles E Bugg 董事 2007年3月18日 A 62439 0 0 $0
GORDON CARL L 董事 2006年5月17日 A 1100000 0 0 $0
John A Montgomery 董事 2003年11月4日 M 46785 0 0 $0

来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖

激进投资者及 5%+ 股东 15 持仓

提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。

申报人 已申报 持股 状态 目的 申报
Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 申报 2018年7月31日 — 初始申报 — SEC
RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. 2018年4月2日 — 初始申报 被动投资 SEC
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 申报 2016年8月16日 — 初始申报 — SEC
Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 申报 2012年10月23日 — 初始申报 并购/出售 SEC
Julian C. Baker, Felix J. Baker ×4 申报 2011年10月13日 — 初始申报 — SEC
L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 申报 2007年8月20日 — 初始申报 — SEC
未披露的报告人, 未披露的报告人, 未披露的报告人 2005年12月7日 — 初始申报 — SEC
未披露的报告人, 未披露的报告人, 未披露的报告人 2005年12月7日 — 初始申报 — SEC
未披露的报告人, 未披露的报告人, 未披露的报告人 2005年12月7日 — 初始申报 — SEC
未披露的报告人 2005年10月13日 — 初始申报 — SEC
未披露的报告人, 未披露的报告人, 未披露的报告人 2004年2月26日 — 初始申报 — SEC
未披露的报告人, 未披露的报告人, 未披露的报告人 2004年2月25日 — 初始申报 — SEC
未披露的报告人, 未披露的报告人, 未披露的报告人 2004年2月24日 — 初始申报 — SEC
Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 申报 2003年10月31日 — 初始申报 — SEC
William W. Featheringill 2002年2月14日 — 初始申报 — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF持仓 由 53 只交易所交易基金持有

权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。

基金 权重 单位 截至 来源
PBE · Invesco Exchange-Traded Fund Trust 2.65% 1023838 SH 2026年8月8日 每日
BBP · ETFis Series Trust I 1.93% 125015 NS 2026年4月30日 N-PORT
ABLS · Abacus FCF ETF Trust 1.26% 1682 NS 2026年4月30日 N-PORT
LABU · Direxion Shares ETF Trust 0.67% 381305 NS 2026年4月30日 N-PORT
FYC · First Trust Exchange-Traded Alpha... 0.54% 612341 NS 2026年4月30日 N-PORT
CALF · Pacer Funds Trust 0.41% 1556494 NS 2026年4月30日 N-PORT
FYX · First Trust Exchange-Traded Alpha... 0.28% 364624 NS 2026年4月30日 N-PORT
BFOR · ALPS ETF Trust 0.25% 59894 NS 2026年5月31日 N-PORT
OMFS · Invesco Exchange-Traded Self-Inde... 0.24% 72535 SH 2026年8月8日 每日
GSSC · Goldman Sachs ETF Trust 0.19% 213133 NS 2026年5月31日 N-PORT
SMLF · iShares Trust 0.17% 758958 SH 2026年8月8日 每日
IBBQ · Invesco Exchange-Traded Fund Trus... 0.16% 13830 SH 2026年8月8日 每日
IBB · iShares Trust 0.15% 1580105 SH 2026年8月8日 每日
ESSC · Strategy Shares 0.15% 4183 NS 2026年4月30日 N-PORT
VTWG · VANGUARD SCOTTSDALE FUNDS 0.14% 249665 SH 2026年8月8日 每日
IWO · iShares Trust 0.13% 2097061 SH 2026年8月8日 每日
BIB · ProShares Trust 0.11% 9271 NS 2026年5月31日 N-PORT
FAD · First Trust Exchange-Traded Alpha... 0.11% 57134 NS 2026年4月30日 N-PORT
BBSC · J.P. Morgan Exchange-Traded Fund ... 0.10% 81871 NS 2026年4月30日 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0.07% 1339774 SH 2026年8月8日 每日
ISCG · iShares Trust 0.07% 73787 SH 2026年8月8日 每日
IWM · iShares Trust 0.07% 5925076 SH 2026年8月8日 每日
PRFZ · Invesco Exchange-Traded Fund Trust 0.07% 206325 SH 2026年8月8日 每日
RSSL · Global X Funds 0.06% 97958 NS 2026年4月30日 N-PORT
DFAS · Dimensional ETF Trust 0.05% 806097 NS 2026年4月30日 N-PORT
ITWO · ProShares Trust 0.05% 10652 NS 2026年5月31日 N-PORT
SCHA · SCHWAB STRATEGIC TRUST 0.05% 1154262 NS 2026年5月31日 N-PORT
VBK · VANGUARD INDEX FUNDS 0.04% 1696014 SH 2026年8月8日 每日
ISCB · iShares Trust 0.03% 10494 SH 2026年8月8日 每日
FHLC · FIDELITY COVINGTON TRUST 0.03% 96151 NS 2026年4月30日 N-PORT
VXF · VANGUARD INDEX FUNDS 0.03% 2837341 SH 2026年8月8日 每日
VHT · VANGUARD WORLD FUND 0.03% 624412 SH 2026年8月8日 每日
UWM · ProShares Trust 0.03% 8331 NS 2026年5月31日 N-PORT
URTY · ProShares Trust 0.02% 8425 NS 2026年5月31日 N-PORT
VB · VANGUARD INDEX FUNDS 0.02% 2922024 SH 2026年8月8日 每日
WSML · iShares Trust 0.02% 11689 SH 2026年8月8日 每日
MSSM · MORGAN STANLEY PATHWAY FUNDS 0.01% 9529 NS 2026年5月31日 N-PORT
HDG · ProShares Trust 0.01% 212 NS 2026年5月31日 N-PORT
ONEQ · Fidelity Commonwealth Trust 0.01% 80493 NS 2026年5月31日 N-PORT
DFUS · Dimensional ETF Trust 0.00% 74317 NS 2026年4月30日 N-PORT
IWV · iShares Trust 0.00% 72218 SH 2026年8月8日 每日
AVUQ · AMERICAN CENTURY ETF TRUST 0.00% 937 NS 2026年5月31日 N-PORT
ITOT · iShares Trust 0.00% 336352 SH 2026年8月8日 每日
SCHB · SCHWAB STRATEGIC TRUST 0.00% 141645 NS 2026年5月31日 N-PORT
TILT · FlexShares Trust 0.00% 6314 NS 2026年4月30日 N-PORT
DFAC · Dimensional ETF Trust 0.00% 34873 NS 2026年4月30日 N-PORT
DFAT · Dimensional ETF Trust 0.00% 8956 NS 2026年4月30日 N-PORT
FSCC · Federated Hermes ETF Trust 0.00% 129 NS 2026年5月31日 N-PORT
DFAU · Dimensional ETF Trust 0.00% 3019 NS 2026年4月30日 N-PORT
VTI · VANGUARD INDEX FUNDS 0.00% 8070274 SH 2026年8月8日 每日